Abstract: For manufacturing a solid administration form comprising at least one active pharmaceutical ingredient, a flowable but setting composite material comprising the at least one active pharmaceutical ingredient is added together and set to generate the solid administration form. The flowable composite material is liquefied and delivered to a discharge unit. Small portions of liquefied composite material are intermittently discharged through an outlet into a setting unit. The flowable composite material comprises a polymer and at least one active pharmaceutical ingredient dispersed or dissolved within the polymer. The small portions are droplets and the solid administration form is generated by adding droplets that stick together before or during the setting of the liquefied composite material. An average diameter of the droplets can be less than 350 ?m. There can be a void space between at least some small portions, resulting in a porous structure of the solid administration form.

Abstract: The present invention relates to a process for the preparation of fluorinated compounds, to novel compounds containing fluorinated end groups, to the use thereof and to compositions comprising novel compounds containing fluorinated end groups.

Abstract: The present invention relates to dibenzofuran and dibenzothiophene derivatives, especially for use as triplet matrix materials in organic electroluminescent devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.

Abstract: In one embodiment, the invention is directed to a method of reading a marking, comprising a stimulation step, wherein a physical challenge according to a predetermined challenge-response authentication scheme corresponding to the PUF is created and applied to a PUF; a detection step, wherein a response generated by the PUF in accordance with the challenge-response authentication scheme in reaction to the challenge is detected and a digital signal representing the response is generated; a processing step, wherein the digital signal is processed in order to generate a hash value of the response by application of a predetermined cryptographic hash function to the digital signal; and an output step, wherein data representing the generated hash value as a first reading result is output.

Abstract: The present invention relates to a method for controlling a condition of a plant.

Abstract: The present invention relates to a composition comprising at least one nanosized light emitting material.

Abstract: The present invention refers to a method for modulating a condition of a biological cell.

Abstract: Compounds of the formula I in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.

Abstract: A device for imaging a bioluminescence reaction of a sample is provided, containing a reflector having a parametric form and extending about a first longitudinal axis (C), a receptacle into which a sample container with a second longitudinal axis can be inserted to be held therein, and a photo sensor with a photosensitive portion. The reflector has an opening through which the sample container can be inserted to a position where the sample container is held in the receptacle. The receptacle is arranged such that, when the sample container with the sample is held in the receptacle, the sample is surrounded by the reflector so that the light emitted from the sample due to the bioluminescence reaction is reflected by the reflector onto the photosensitive portion of the photo sensor. And an apparatus is provided including the device.

Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.

Abstract: The invention relates to the field of controlling the growth of an organism, or a plurality of organisms, such as particularly one more plants. Specifically, the invention is directed to a modulating system for modulating light to which an organism is to be exposed.

Abstract: The present invention relates to compositions of highly concentrated protein formulations showing reduced viscosity.

Abstract: Electronic device and associated methods with multiple well areas located on a common substrate, where each well area is defined by at least three bank structures that form the side walls of the well area. Within each well area, there are at least two electrode segments where the electrode segments are separated laterally by at least one insulating bank where the insulating bank(s) are thicker than the electrode segments. There is at least one charge transporting layer completely filling the well area in direct contact and overlying both the electrode segments and the insulating bank(s). The well areas are filled using solution methods such as inkjet. Such devices have improved uniformity across the active areas.

Abstract: The invention relates to a liquid-crystalline medium, characterised in that it comprises one or more compounds of the formula IA, and one or more compounds of the formula IB, in which RA, RB, XA, XB and Y1-13 have the meanings indicated in Claim 1, and to the use thereof for electro-optical purposes, in particular for shutter glasses, 3D applications, in TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, PS-FFS and PS-VA-IPS displays.

Abstract: The invention relates to a computer-implemented method, system and computer program for tokenization of a physical object. The method comprises generating or receiving object identification data based on an inspection of the physical object, the object identification data comprising at least one cryptographic hash value as a collision-resistant virtual representation of the physical object; and generating a non-certified token being assigned to the physical object and representing the object identification data. The invention further relates to a computer-implemented method, system and computer program of certifying a token including object identification data. Moreover, the invention relates to a computer-implemented method, system and computer program of tokenization of a process.

Abstract: The invention relates to a liquid-crystalline medium comprising one or more compounds of the formula IA and, one or more compounds of formula BS wherein the occurring groups have the meanings indicated in claim 1, and to the use thereof in an active-matrix display, in particular in a VA, IPS, U-IPS, FFS, UB-FFS, SA-VA, SA-FFS, PS-VA, PS-OCB, PS-IPS, PS-FFS, PS-UB-FFS, PS-posi-VA, PS-TN, polymer stabilised SA-VA or polymer stabilised SA-FFS display.

Abstract: A method and apparatus for improved switching speed and/or tunability for radio-frequency (RF) devices are described. In one embodiment, a liquid crystal (LC) component comprises an LC structure in a mixture with right-handed (R) and left-handed (S) chiral dopants.

Abstract: ?-amino boronic acid derivatives are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer.

Abstract: Liquid-crystalline media (LC media) comprising self-aligning mesogens (self-alignment additives) which effect homeotropic (vertical) alignment of the LC media at a surface or the cell walls of a liquid-crystal display (LC display). The self-alignment additives contain five-ring systems. LC displays having homeotropic alignment of the liquid-crystalline medium (LC medium) without conventional alignment layers are provided.

Abstract: The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.